R
Robert Mason
Researcher at University of Queensland
Publications - 114
Citations - 3297
Robert Mason is an academic researcher from University of Queensland. The author has contributed to research in topics: Cancer & Esophagectomy. The author has an hindex of 27, co-authored 106 publications receiving 2772 citations. Previous affiliations of Robert Mason include Karolinska Institutet & King's College London.
Papers
More filters
Journal ArticleDOI
The expanding role of primary care in cancer control
Greg Rubin,Annette J. Berendsen,S Michael Crawford,Rachel Dommett,Craig C. Earle,Jon Emery,Tom Fahey,Luigi Grassi,Eva Grunfeld,Sumit Gupta,Willie Hamilton,Sara Hiom,David J. Hunter,Georgios Lyratzopoulos,Una Macleod,Robert Mason,Geoffrey Mitchell,Richard D Neal,Michael D Peake,Martin Roland,Bohumil Seifert,Jeff Sisler,Jonathan Sussman,Stephen H. Taplin,Peter Vedsted,Teja Voruganti,Fiona M Walter,Jane Wardle,Eila Watson,David Weller,Richard C. Wender,Jeremy Whelan,James A. Whitlock,Clare Wilkinson,Niek J. de Wit,Camilla Zimmermann +35 more
TL;DR: This Commission considers how this expanding role for primary care can work for cancer control, which has long been dominated by highly technical interventions centred on treatment, and in which the contribution of primary care has been largely perceived as marginal.
Journal ArticleDOI
Tumor Stage After Neoadjuvant Chemotherapy Determines Survival After Surgery for Adenocarcinoma of the Esophagus and Esophagogastric Junction
Andrew Davies,James A. Gossage,J Zylstra,Fredrik Mattsson,Jesper Lagergren,Nick Maisey,Elizabeth C Smyth,David Cunningham,William H. Allum,Robert Mason +9 more
TL;DR: The stage of esophageal or esophagogastric junction adenocarcinoma after neoadjuvant chemotherapy determines prognosis rather than the clinical stage before neoad juvant chemotherapy, indicating the importance of focusing on postchemotherapy staging to more accurately predict outcome and eligibility for surgery.
Journal ArticleDOI
Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer
Connie Yip,Vicky Goh,Vicky Goh,Andrew Davies,James A. Gossage,Rosalind Mitchell-Hay,Orla Hynes,Nick Maisey,Paul Ross,Andrew Gaya,David Landau,David Landau,Gary Cook,Nyree Griffin,Robert Mason +14 more
TL;DR: Sarcopenia was more prevalent after neoadjuvant chemotherapy, and loss of FM, differential loss of VA/SA and skeletal muscle were associated with risk of CRM positivity, while changes in body composition did not affect perioperative complications and survival.
Journal ArticleDOI
A randomised prospective comparison of the Flamingo Wallstent and Ultraflex stent for palliation of dysphagia associated with lower third oesophageal carcinoma
TL;DR: The two types of stent are equally effective in the palliation of dysphagia associated with lower third oesophageal malignancy and the complication rates associated with their use are comparable.
Journal ArticleDOI
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
Y.J.L. Jansen,Elisa A. Rozeman,Robert Mason,Simone M. Goldinger,M.H. Geukes Foppen,Lise Hoejberg,Henrik Schmidt,J.V. van Thienen,J.B.A.G. Haanen,Leena Tiainen,Inge Marie Svane,Siru Mäkelä,Teofila Seremet,A. Arance,Reinhard Dummer,Lars Bastholt,Marta Nyakas,Oddbjørn Straume,Alexander M. Menzies,Alexander M. Menzies,Georgina V. Long,Georgina V. Long,Victoria Atkinson,Christian U. Blank,Bart Neyns +24 more
TL;DR: In this real-world cohort of advanced melanoma patients discontinuing anti- PD-1 therapy in the absence of TLT or PD, the duration of anti-PD-1 Therapy was shorter when compared to clinical trials.